Eutilex Secures Russian Patent for Blood and Solid Tumor-Targeting CAR-T Therapy

[Asia Economy Reporter Kwon Jaehee] Eutilex announced on the 16th that it has secured a Russian patent for the blood and solid tumor-targeting CAR-T therapy 'EU301 (MVR CAR-T)'.

This patented technology has entered a total of 13 countries, including the United States, Korea, and Europe, through PCT (international patent). The company had already secured a patent in the United States last year.

EU301 is a CAR-T therapy targeting HLA-DR.

In the case of CD-19, the target of existing CAR-T therapies, it is expressed on normal B cells as well, which limits the ability to distinguish and attack cancer cells from normal cells. In contrast, the MVR antibody of this patented technology has a significantly lower binding affinity to normal cells in the body, offering the advantage of higher safety.

The company explained, "By designing MVR with sequence variations to have various binding affinities to the HLA-DR antigen, it features ease of creating chimeric antigen receptors and CAR-T cell therapies using them."